^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Clear Cell Renal Cell Carcinoma

    Related cancers:
    1d
    CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Cdactin-O (CBM588)
    1d
    XmAb819-01: Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=307, Recruiting, Xencor, Inc. | N=95 --> 307 | Trial completion date: Nov 2027 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Enrollment change • Trial completion date • Trial primary completion date
    1d
    E2810: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery (clinicaltrials.gov)
    P3, N=129, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    pazopanib
    2d
    Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P1/2, N=47, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    mTOR (Mechanistic target of rapamycin kinase)
    |
    Jingzhuda (entinostat) • Proleukin (aldesleukin)
    2d
    A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) (clinicaltrials.gov)
    P1/2, N=234, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • pumitamig (BNT327)
    2d
    Intracellular complement Factor H promotes tumor progression through modulation of cell cycle and actin cytoskeleton. (PubMed, Commun Biol)
    Moreover, in ccRCC cancer cells, FH also regulates cytoskeleton organization and cell morphology, potentially, via interaction with the actin capping CapZ complex. Therefore, complement FH acts as a multitasking effector, regulating cell cycle and actin polymerization, challenging the paradigm of extracellular space-restricted functioning, considered for many complement proteins.
    Journal
    |
    E2F3 (E2F transcription factor 3)
    2d
    A pan-cancer portrait of PDK1: From oncogenic driver to context-dependent immunological regulator. (PubMed, Cancer Treat Res Commun)
    In KIRC, in particular, high PDK1 levels were linked to high TIL and PD-L1, which supports the idea that PDK1 is a combined immunological and prognostic biomarker. These results define the multifactorial functions of PDK1 in tumorigenesis and immunoregulation, which opens the path to the creation of PDK1-targeted therapies in clinical oncology.
    Journal • PD(L)-1 Biomarker • IO biomarker • Pan tumor
    |
    PD-L1 (Programmed death ligand 1) • PDK1 (Pyruvate Dehydrogenase Kinase 1)
    3d
    Activation of the PI3K/AKT pathway by EDIL3 induces EMT and promotes tumor progression in clear cell renal cell carcinoma. (PubMed, Mol Genet Genomics)
    Mechanistically, EDIL3 promoted epithelial-mesenchymal transition (EMT), as evidenced by downregulation of E-cadherin and upregulation of N-cadherin and Vimentin. Further analyses revealed that EDIL3 activated the PI3K/AKT signaling pathway, and sustained activation of this pathway effectively reversed the suppression of EMT and malignant phenotypes induced by EDIL3 depletion.Collectively, our findings identify EDIL3 as a critical regulator of ccRCC cell malignancy by linking extracellular matrix dynamics to PI3K/AKT-driven EMT programs, thereby providing mechanistic insight into its role in ccRCC progression.
    Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • EDIL3 (EGF Like Repeats And Discoidin Domains 3)
    3d
    CDFF332A12101: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (clinicaltrials.gov)
    P1, N=40, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Business decision and not related to safety concerns
    Trial termination • IO biomarker • First-in-human
    |
    VHL (von Hippel-Lindau tumor suppressor) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • EPAS1 (Endothelial PAS domain protein 1) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SDHD (Succinate Dehydrogenase Complex Subunit D) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2)
    |
    VHL mutation
    |
    everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)
    3d
    Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma. (PubMed, J Immunother Cancer)
    Greater subcutaneous adiposity and skeletal muscle mass were associated with shorter PFS among patients with metastatic ccRCC treated with 1L nivolumab+ipilimumab. These findings support the concept that host body composition influences the heterogeneous clinical benefit observed with ICI in metastatic ccRCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IDO1 (Indoleamine 2,3-dioxygenase 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    3d
    Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (clinicaltrials.gov)
    P3, N=1175, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Jan 2028 | Trial primary completion date: Sep 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • ABP 206 (nivolumab biosimilar)
    4d
    C6461008: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer (clinicaltrials.gov)
    P1/2, N=224, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open